Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414).
- DOI
- 10.1016/j.jtocrr.2020.100104
- Published
- 2021 Feb
- Container
- JTO clinical and research reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2020.100104,
title = {Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414).},
author = {Pillai RN and Ramalingam SS and Thayu M and Lorenzini P and Alvarez Arias DA and Moy C and Hutnick N and Knoblauch R and Feng H and Kane C and Horn L and Reck M and Ponce S and LUC2001 Investigators},
year = {2021},
journal = {JTO clinical and research reports},
doi = {10.1016/j.jtocrr.2020.100104},
url = {https://doi.org/10.1016/j.jtocrr.2020.100104}
}RIS
TY - JOUR TI - Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414). AU - Pillai RN AU - Ramalingam SS AU - Thayu M AU - Lorenzini P AU - Alvarez Arias DA AU - Moy C AU - Hutnick N AU - Knoblauch R AU - Feng H AU - Kane C AU - Horn L AU - Reck M AU - Ponce S AU - LUC2001 Investigators PY - 2021 JO - JTO clinical and research reports DO - 10.1016/j.jtocrr.2020.100104 UR - https://doi.org/10.1016/j.jtocrr.2020.100104 ER -
APA
RN, P., SS, R., M, T., P, L., DA, A. A., C, M., N, H., R, K., H, F., C, K., L, H., M, R., S, P., & Investigators, L. (2021). Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414).. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2020.100104
Source records
- pubmed · retrieved 2026-09-26T13:27:52.808Z